SEARCH

SEARCH BY CITATION

References

  • 1
    Lindheimer MD, Umans JG. Explaining and predicting preeclampsia. N Engl J Med 2006;355:10568.
  • 2
    Baumann MU, Bersinger NA, Surbek DV. Serum markers for predicting pre-eclampsia. Mol Aspects Med 2007;28:22744.
  • 3
    Bantscheff M, Schirle M, Sweetman G, Rick J, Kuster B. Quantitative mass spectrometry in proteomics: a critical review. Anal Bioanal Chem 2007;389:101731.
  • 4
    Pham TK, Chong PK, Gan CS, Wright PC. Proteomic analysis of Saccharomyces cerevisiae under high gravity fermentation conditions. J Proteome Res 2006;5:34119.
  • 5
    Chakravarti B, Gallagher SR, Chakravarti DN. Difference gel electrophoresis (DIGE) using CyDye DIGE fluor minimal dyes. Curr Protoc Mol Biol 2005. Chapter 10: Unit 10 23.
  • 6
    Anderson NL, Anderson NG. The human plasma proteome: history, character, and diagnostic prospects. Mol Cell Proteomics 2002;1:84567.
  • 7
    Aggarwal K, Choe LH, Lee KH. Shotgun proteomics using the iTRAQ isobaric tags. Brief Funct Genomic Proteomic 2006;5:11220.
  • 8
    Pierce A, Unwin RD, Evans CA, Griffiths S, Carney L, Zhang L, et al. Eight-channel iTRAQ enables comparison of the activity of 6 leukaemogenic tyrosine kinases. Mol Cell Proteomics 2007;7:85363.
  • 9
    Myers J, Mires G, Macleod M, Baker P. In preeclampsia, the circulating factors capable of altering in vitro endothelial function precede clinical disease. Hypertension 2005;45:25863.
  • 10
    Brown MA, Lindheimer MD, de Swiet M, Van Assche A, Mountquin JM. The classification and diagnosis of the hypertensive disorders of pregnancy: statement from the International Society for the Study of Hypertension in Pregnancy (ISSHP). Hypertens Pregnancy 2001;20:IXXIV.
  • 11
    Shilov IV, Seymour SL, Patel AA, Loboda A, Tang WH, et al. The Paragon Algorithm, a next generation search engine that uses sequence temperature values and feature probabilities to identify peptides from tandem mass spectra. Mol Cell Proteomics 2007;6:163855.
  • 12
    Unwin RD, Pierce A, Watson RB, Sternberg DW, Whetton AD. Quantitative proteomic analysis using isobaric protein tags enables rapid comparison of changes in transcript and protein levels in transformed cells. Mol Cell Proteomics 2005;4:92435.
  • 13
    Redman CW, Sacks GP, Sargent IL Preeclampsia: an excessive maternal inflammatory response to pregnancy. Am J Obstet Gynecol 1999;180(2 Pt 1):499506.
  • 14
    Spencer K, Yu CK, Savvidou M, Papageorghiou AT, Nicolaides KH. Prediction of pre-eclampsia by uterine artery Doppler ultrasonography and maternal serum pregnancy-associated plasma protein-A, free beta-human chorionic gonadotropin, activin A and inhibin A at 22 + 0 to 24 + 6 weeks’ gestation. Ultrasound Obstet Gynecol 2006;27:65863.
  • 15
    Bersinger NA, Smarason AK, Muttukrishna S, Groome NP, Redman CW. Women with preeclampsia have increased serum levels of pregnancy-associated plasma protein A (PAPP-A), inhibin A, activin A and soluble E-selectin. Hypertens Pregnancy 2003;22:4555.
  • 16
    Bersinger NA, Odegard RA. Second- and third-trimester serum levels of placental proteins in preeclampsia and small-for-gestational age pregnancies. Acta Obstet Gynecol Scand, 2004;83:3745.
  • 17
    Okazaki S, Sekizawa A, Purwosunu Y, Farina A, Wibowo N, Okai T. Placenta-derived, cellular messenger RNA expression in the maternal blood of preeclamptic women. Obstet Gynecol 2007;110:11306.
  • 18
    Watanabe H, Hamada H, Yamada N, Sohda S, Yamakawa-Kobayashi K, Yoshikawa H, et al. Proteome analysis reveals elevated serum levels of clusterin in patients with preeclampsia. Proteomics 2004;4:53743.
  • 19
    Mekbeb T. The association of serum proteins with preeclampsia. Ethiop Med J 1990;28:914.
  • 20
    De Vivo A, Baviera G, Giordano D, Todarello G, Corrado F, D'Anna R. Endoglin, PlGF and sFlt-1 as markers for predicting pre-eclampsia. Acta Obstet Gynecol Scand 2008;87:83742.
  • 21
    Jeyabalan A, McGonigal S, Gilmour C, Hubel CA, Rajakumar A. Circulating and placental endoglin concentrations in pregnancies complicated by intrauterine growth restriction and preeclampsia. Placenta 2008;29:55563.
  • 22
    Romero R, Nien JK, Espinoza J, Todem D, Fu W, et al. A longitudinal study of angiogenic (placental growth factor) and anti-angiogenic (soluble endoglin and soluble vascular endothelial growth factor receptor-1) factors in normal pregnancy and patients destined to develop preeclampsia and deliver a small for gestational age neonate. J Matern Fetal Neonatal Med 2008;21:923.
  • 23
    Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006;355:9921005.